The Journal of family practice
-
The increasing prevalence of type 1 diabetes (T1D) suggests family physicians will regularly see first-degree relatives of patients with T1D with the genetic propensity for developing T1D. T1D autoantibody screening by family clinicians addresses an important need to identify at-risk individuals early and achieve short- and long-term health benefits. Multiple T1D screening options and programs are available to clinicians that provide patient education, testing, result analysis, follow-up, and opportunity for participation in T1D prevention trials. The provider-patient relationship in family medicine places clinicians in a unique position to provide monitoring and followup crucial to family members with positive autoantibody results.
-
At the end of the activity, participants will be able to:Summarize important findings and trends involving women and atherosclerotic cardiovascular disease (ASCVD). Characterize the multiple cardiometabolic changes that occur during menopause and the associated ASCVD risk. Discuss the challenges of assessing ASCVD risk and dyslipidemia management in women. Identify women with elevated ASCVD risk and implement guideline-recommended statin therapy.
-
This oral anti-inflammatory agent may offer a low-cost option for prevention of cardiovascular events in this patient population.
-
Chronic kidney disease (CKD) remains underrecognized by patients and clinicians in the primary care setting, largely due to its asymptomatic presentation in early stages. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have demonstrated kidney-protective effects in clinical trials-including in patients with and without type 2 diabetes (T2D)-and there are several proposed mechanisms for these benefits. Dapagliflozin and canagliflozin are SGLT2 inhibitors with indications for CKD, and only dapagliflozin is indicated for CKD in patients without T2D. Clinically relevant adverse events associated with SGLT-2 inhibitors include volume depletion, diabetic ketoacidosis, and genital mycotic infections.
-
At the end of the activity, participants will be able to:Implement evidence-based methods for cognitive impairment screening in primary care. Identify correct diagnostic criteria for mild cognitive impairment (MCI) and Alzheimer disease (AD) based on current guideline recommendations. Design appropriate and effective treatment plans for patients with MCI and AD and refer to a specialist when necessary. Describe advances in testing and treatment for AD that may impact dementia care.